1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6B9B48B3104F4A73A00258B1D0044E7D2
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/global-medical-affairs-resourcing-benchmark-for-heor-functions?opendocument
18
19opendocument
203.236.142.143
21
22
23best-in-class.com
24/bestp/domrep.nsf
25BMR




» Products & Services » » Medical Affairs » Health Outcomes

Global Medical Affairs Resourcing Benchmark for HEOR Functions

ID: POP-380


Features:

9 Info Graphics

16 Data Graphics

430+ Metrics

23 Narratives


Pages: 32


Published: 2024


Delivery Format: Shipped


 

License Options:


Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
Strategic resource allocation within the Health Economics and Outcomes Research (HEOR) function is critical to ensure productivity and cost-effectiveness in support of high impact. A key consideration in resourcing the HEOR function is determining the types and degree of outsourcing. The decision to insource or outsource HEOR activities can redefine core capabilities, drastically affect costs, and strengthen support across therapeutic domains.

Best Practices, LLC conducted this benchmarking research to probe the intricacies of HEOR resourcing within mid-sized and large biopharma organizations. The report investigates productivity metrics, outsourcing benchmarks, spend patterns, and staffing dynamics - within outsourcing, insourcing and hybrid models. These insights will provide HEOR leadership with the knowledge to navigate complexities effectively, enhance productivity, and drive sustainable growth within HEOR functions (both it resides within Medical Affairs and in other parts of the organizations).

Industries Profiled:
Pharmaceutical; Biopharmaceutical; Biotech; Consumer Products; Health Care; Clinical Research; Laboratories


Companies Profiled:
AbbVie; Acadia Pharmaceuticals; Agenus; Alexion Pharmaceuticals; Astellas; Dompé; Fidia Pharma USA Inc.; Gilead Sciences; Novartis; Novo Nordisk; Organon; Pfizer; Pixacore; Protagonist Therapeutics; Regeneron; Sanofi; Sobi; Teva Pharmaceuticals; United Therapeutics; UCB Pharma

Study Snapshot

This report offers tailored benchmarks and insights focused on the HEOR function. The data from this research is drawn by engaging 22 Medical leaders from 20 leading mid-cap and large biopharma organizations, with expertise encompassing HEOR, Medical Publications & Strategy. HEOR insights are meticulously distilled to ensure relevance and applicability within the scope of this research.

Key topics covered in this report include:

  • HEOR Outsourcing Trends
  • Scope of Support
  • Productivity and Outsourced Capabilities
  • HEOR Staffing Dynamics
  • Hybrid Resourcing Benefits

Key Findings

Select key insights uncovered from this report are noted below. Detailed findings are available in the full report.

  • Outsourcing Is Ubiquitous Across Global HEOR: The majority of surveyed mid-cap and large companies predominantly outsource most activities, relying significantly on outsourcing for their operations.
  • Factors Driving Insourcing in HEOR: 63% of companies say it is “absolutely critical” to retain some degree of in-house HEOR expertise, and many believe insourced research yields higher quality work product.
Table of Contents

Sr. No.
Topic
Slide No.
I.
Executive SummaryPg. 3-8
II.
HEOR Resourcing: Scope of Support & AlignmentPg. 9-13
III.
Productivity & Capabilities of Outsourced vs. Insourced HEOR ModelsPg. 14-21
IV.
Staffing & Resourcing TrendsPg. 22-31
V.
About Best Practices, LLCPg. 32

    List of Charts & Exhibits

    I. Executive Summary

    • Research methodology and scope overview
    • Global HEOR benchmark study partners
    • Overarching findings for HEOR resourcing and service delivery
    • HEOR industry benchmarks
    • Study summary for HEOR leadership resourcing decisions

    II. HEOR Resourcing: Scope of Support & Alignment

    • HEOR group alignment
    • HEOR support across the product lifecycle
    • Scope of HEOR support and total annual HEOR spend

    III. Productivity & Capabilities of Outsourced vs. Insourced HEOR Models

    • Average annual volume of HEOR activities
    • Interview narratives around the use of hybrid models
    • Extent of outsourcing in HEOR activities
    • Outsourcing x Productivity Matrix: RWE/Claims/HCRU/Epidemiology/Costing studies/
    • External control arms development
    • Outsourcing x Productivity Matrix: Systemic/Targeted literature reviews
    • Outsourcing x Productivity Matrix: AMCP/Global value dossiers
    • Outsourcing x Productivity Matrix: Budget impact models

    IV. Staffing & Resourcing Trends

    • Number of FTEs (full-time equivalent employees) and CWs (contract workers) dedicated to each HEOR role
    • Staffing levels per brand
    • Benefits of an outsourced HEOR model
    • Benefits of an in-house HEOR model
    • Quantifying the benefits of HEOR resourcing model
    • Key HEOR trends
    • Lessons learned relating to the outsourcing and insourcing of HEOR capabilities
    • Geographical responsibility of benchmark partners